The Role of Antidepressants in the Management of Fibromyalgia Syndrome: A Systematic Review and Meta-Analysis
CNS Drugs,  Evidence Based Medicine  Clinical Article

Hauser W et al. – The tricyclic antidepressant (TCA) amitriptyline and the serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) duloxetine and milnacipran are first–line options for the treatment of fibromyalgia syndrome (FMS) patients. Physicians and patients should be realistic about the potential benefits of antidepressants in FMS. A small number of patients experience a substantial symptom relief with no or minor adverse effects. However, a remarkable number of patients dropout of therapy because of intolerable adverse effects or experience only a small relief of symptoms, which does not outweigh the adverse effects.

Methods
  • Studies with a randomized controlled trial (RCT) design comparing any types of antidepressants with pharmacological placebo or head–to–head comparisons of different types of antidepressants in FMS patients were included.
  • RCTs in which antidepressants were combined with any other defined treatment or antidepressants were tested against anything but drug placebo were excluded.
  • Patients diagnosed with FMS according to predefined criteria of any age were included.
  • To be included, studies had to assess at least one key domain of FMS (pain, sleep, fatigue, health–related quality of life [HRQOL]) as outcomes of efficacy and report total treatment discontinuation rates and/or dropout rates due to adverse events as outcomes for harms.
  • Data were extracted according to protocols of previous systematic reviews on antidepressants in FMS.
  • Methodology quality was assessed by the van Tulder score.
  • Standardized mean differences (SMD) were calculated for continuous outcomes by means and standard deviations and relative risks (RR) for 30% pain reduction and total dropout rate for comparisons of antidepressants with placebo.
  • Examination of the combined results was performed by a random effects model.
  • The authors used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD.
  • Heterogeneity was tested by the I2 statistic.
  • Thirty–five studies were included in the meta–analysis.

Results
  • The SMDs of serotonin noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) on pain, sleep, fatigue, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect size on pain was small and the ones on sleep, fatigue, depression and HRQOL were not substantial.
  • 1481/3528 (42.0%) patients with SNRIs and 737/2304 (32.0%) patients with placebo reported a 30% pain reduction (number needed to treat [NNT] 10.0; 95% CI 8.00, 13.4; I2=4%).
  • The RR of dropouts due to adverse events was 1.83 (95% CI 1.53, 2.18; I2=33%).
  • The SMDs of selective serotonin reuptake inhibitors (SSRIs) on pain, sleep, depression and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain, depression and HRQOL were small and the one on sleep not substantial.
  • 72/198 (36.4%) patients with SSRIs and 40/194 (20.6%) patients with placebo reported a 30% pain reduction (NNT 6.3; 95% CI 4.1, 14.1).
  • The RR of dropouts due to adverse events was 1.60 (95% CI 0.84, 3.04; I2=0%).
  • The SMDs of tricyclic antidepressants (TCAs) on pain, sleep, fatigue and HRQOL were significant.
  • Based on Cohen's categories, the effect sizes on pain and sleep were moderate and the ones on fatigue and HRQOL were small.
  • 140/290 (48.3%) patients with TCAs and 70/252 (27.8%) patients with placebo reported a 30% pain reduction (NNT 4.9; 95% CI 3.5, 8.0).
  • The RR of dropouts due to adverse events was 0.84 (95% CI 0.46, 1.52; I2=0%).

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Blood manganese levels in relation to comorbid behavioral and emotional problems in children with attention-deficit/hyperactivity disorder Psychiatry Research, November 4, 2014    Clinical Article

3 Maternal age at childbirth and risk for ADHD in offspring: a population-based cohort study International Journal of Epidemiology, November 18, 2014    Clinical Article

4 The influence of inflammatory cytokines in physiopathology of suicidal behavior Journal of Affective Disorders, November 5, 2014    Evidence Based Medicine    Review Article

5 Maternal use of selective serotonin reuptake inhibitors and risk of miscarriage - assessing potential biases Paediatric and Perinatal Epidemiology, November 12, 2014    Clinical Article

6 Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials JAMA Psychiatry, October 22, 2014    Evidence Based Medicine    Clinical Article

7 Birth by caesarean section and development of autism spectrum disorder and attention-deficit/hyperactivity disorder: A systematic review and meta-analysis Journal of Child Psychology and Psychiatry, November 19, 2014    Evidence Based Medicine

8 Investigation of the Montreal Cognitive Assessment (MoCA) as a cognitive screener in severe mental illness Psychiatry Research, November 10, 2014    Clinical Article

9 Is depression associated with increased oxidative stress?: A systematic review and meta-analysis Psychoneuroendocrinology, November 7, 2014    Evidence Based Medicine

10 Obesity and major depression: Body-mass index (BMI) is associated with a severe course of disease and specific neurostructural alterations Psychoneuroendocrinology, November 6, 2014    Clinical Article

11 Serum dehydroepiandrosterone sulfate and incident depression in the elderly: The Pro.V.A Study The American Journal of Geriatric Psychiatry, November 24, 2014    Clinical Article

12 Effects of perinatal mental disorders on the fetus and child The Lancet, November 21, 2014    Evidence Based Medicine    Clinical Article

13 Antidepressant–induced sexual dysfunction during treatment with fluoxetine, sertraline, and trazodone: A randomized controlled trial General Hospital Psychiatry, November 7, 2014    Clinical Article

14 The serotonin-N-acetylserotonin–melatonin pathway as a biomarker for autism spectrum disorders Full Text Translational Psychiatry, November 26, 2014    Free full text    Clinical Article

15 Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period The Lancet, November 20, 2014    Evidence Based Medicine

16 Comparative efficacy and acceptability of drug treatments for bipolar depression: A multiple-treatments meta-analysis Acta Psychiatrica Scandinavica, October 10, 2014    Evidence Based Medicine    Clinical Article

17 Behavioral activation therapy for return to work in medication-responsive chronic depression with persistent psychosocial dysfunction Comprehensive Psychiatry, November 13, 2014    Clinical Article

18 Specific and common genes implicated across major mental disorders: A review of meta-analysis studies Journal of Psychiatric Research, November 17, 2014    Review Article

19 Association between toll-like receptors expression and major depressive disorder Psychiatry Research, November 11, 2014    Clinical Article

20 The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial Psychiatry Research, November 4, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore